Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...

MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

It is 20 years since the demonstration that immune stimulation of metastatic tumors with interleukin-2 (IL-2) could cause the regression of established human cancers. 1 IL-2 is a lymphocyte ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.